Apollo Endosurgery, Inc. Logo

Apollo Endosurgery, Inc.

APEN

(0.0)
Stock Price

10,00 USD

-39.13% ROA

-84.92% ROE

-10.2x PER

Market Cap.

579.718.970,00 USD

175.08% DER

0% Yield

-51.84% NPM

Apollo Endosurgery, Inc. Stock Analysis

Apollo Endosurgery, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Apollo Endosurgery, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Negative ROE (-89.48%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (-39.13%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

3 PBV

The stock's elevated P/BV ratio (9.28x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

4 DER

The company has a high debt to equity ratio (175%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-16) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Apollo Endosurgery, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Apollo Endosurgery, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Apollo Endosurgery, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Apollo Endosurgery, Inc. Revenue
Year Revenue Growth
2005 743.273
2006 511.862 -45.21%
2007 372.348 -37.47%
2008 2.861.149 86.99%
2009 11.909.270 75.98%
2010 7.835.552 -51.99%
2011 9.386.863 16.53%
2012 6.688.153 -40.35%
2013 7.986.762 16.26%
2014 5.080.463 -57.21%
2015 1.599.763 -217.58%
2016 64.868.000 97.53%
2017 64.310.000 -0.87%
2018 60.854.000 -5.68%
2019 50.713.000 -20%
2020 42.048.000 -20.61%
2021 62.989.000 33.25%
2022 85.256.000 26.12%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Apollo Endosurgery, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2005 1.482.410
2006 4.044.947 63.35%
2007 12.418.554 67.43%
2008 10.116.124 -22.76%
2009 6.628.200 -52.62%
2010 7.819.545 15.24%
2011 9.726.794 19.61%
2012 8.158.632 -19.22%
2013 11.343.448 28.08%
2014 18.126.701 37.42%
2015 8.513.974 -112.91%
2016 7.805.000 -9.08%
2017 8.299.000 5.95%
2018 12.176.000 31.84%
2019 10.384.000 -17.26%
2020 7.670.000 -35.38%
2021 9.524.000 19.47%
2022 13.904.000 31.5%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Apollo Endosurgery, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 4.480.260 100%
2009 3.479.326 -28.77%
2010 4.504.802 22.76%
2011 0 0%
2012 4.091.233 100%
2013 4.234.613 3.39%
2014 4.758.831 11.02%
2015 3.946.147 -20.59%
2016 13.625.000 71.04%
2017 13.722.000 0.71%
2018 13.436.000 -2.13%
2019 13.588.000 1.12%
2020 11.062.000 -22.83%
2021 18.448.000 40.04%
2022 20.476.000 9.9%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Apollo Endosurgery, Inc. EBITDA
Year EBITDA Growth
2005 -2.558.472
2006 -5.555.177 53.94%
2007 -14.907.374 62.74%
2008 -11.232.847 -32.71%
2009 4.159.700 370.04%
2010 -4.436.870 193.75%
2011 -2.972.134 -49.28%
2012 -2.564.873 -15.88%
2013 -6.368.467 59.73%
2014 -16.338.963 61.02%
2015 -9.543.318 -71.21%
2016 -13.520.000 29.41%
2017 -12.763.000 -5.93%
2018 -32.241.000 60.41%
2019 -26.619.000 -21.12%
2020 -13.488.000 -97.35%
2021 -17.185.000 21.51%
2022 -30.280.000 43.25%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Apollo Endosurgery, Inc. Gross Profit
Year Gross Profit Growth
2005 743.273
2006 511.862 -45.21%
2007 372.348 -37.47%
2008 2.861.149 86.99%
2009 11.909.270 75.98%
2010 7.835.552 -51.99%
2011 9.386.863 16.53%
2012 6.688.153 -40.35%
2013 7.986.762 16.26%
2014 5.080.463 -57.21%
2015 1.599.763 -217.58%
2016 39.613.000 95.96%
2017 39.732.000 0.3%
2018 33.194.000 -19.7%
2019 25.675.000 -29.29%
2020 22.242.000 -15.43%
2021 34.959.000 36.38%
2022 45.428.000 23.05%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Apollo Endosurgery, Inc. Net Profit
Year Net Profit Growth
2005 -2.796.773
2006 -5.604.743 50.1%
2007 -15.091.760 62.86%
2008 -11.459.985 -31.69%
2009 3.983.010 387.72%
2010 -4.602.174 186.55%
2011 -3.114.127 -47.78%
2012 -2.752.374 -13.14%
2013 -6.564.691 58.07%
2014 -16.555.051 60.35%
2015 -10.010.306 -65.38%
2016 -41.167.000 75.68%
2017 -27.292.000 -50.84%
2018 -45.787.000 40.39%
2019 -27.432.000 -66.91%
2020 -22.611.000 -21.32%
2021 -24.682.000 8.39%
2022 -38.212.000 35.41%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Apollo Endosurgery, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 -366
2006 -124 -196.75%
2007 -210 41.15%
2008 -129 -63.28%
2009 40 428.21%
2010 -44 188.64%
2011 -27 -69.23%
2012 -20 -36.84%
2013 -38 48.65%
2014 -77 51.95%
2015 -30 -165.52%
2016 -106 72.38%
2017 -2 -5150%
2018 -2 0%
2019 -1 -100%
2020 -1 0%
2021 -1 0%
2022 -1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Apollo Endosurgery, Inc. Free Cashflow
Year Free Cashflow Growth
2005 -1.352.484
2006 -4.752.994 71.54%
2007 -11.195.385 57.55%
2008 -6.311.467 -77.38%
2009 -1.624.641 -288.48%
2010 -4.054.344 59.93%
2011 7.573.034 153.54%
2012 -8.657.507 187.47%
2013 -13.540.202 36.06%
2014 -15.722.326 13.88%
2015 -12.159.689 -29.3%
2016 -15.266.000 20.35%
2017 -15.457.000 1.24%
2018 -26.000.000 40.55%
2019 -26.602.000 2.26%
2020 -21.442.000 -24.06%
2021 -15.910.000 -34.77%
2022 -10.815.000 -47.11%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Apollo Endosurgery, Inc. Operating Cashflow
Year Operating Cashflow Growth
2005 -1.311.648
2006 -4.459.884 70.59%
2007 -10.918.841 59.15%
2008 -6.192.041 -76.34%
2009 -1.054.786 -487.04%
2010 -3.585.804 70.58%
2011 8.062.083 144.48%
2012 -8.313.201 196.98%
2013 -13.149.147 36.78%
2014 -15.186.411 13.42%
2015 -11.868.537 -27.96%
2016 -12.901.000 8%
2017 -13.320.000 3.15%
2018 -23.119.000 42.39%
2019 -25.622.000 9.77%
2020 -20.812.000 -23.11%
2021 -14.454.000 -43.99%
2022 -10.303.000 -40.29%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Apollo Endosurgery, Inc. Capital Expenditure
Year Capital Expenditure Growth
2005 40.836
2006 293.110 86.07%
2007 276.544 -5.99%
2008 119.426 -131.56%
2009 569.855 79.04%
2010 468.540 -21.62%
2011 489.049 4.19%
2012 344.306 -42.04%
2013 391.055 11.95%
2014 535.915 27.03%
2015 291.152 -84.07%
2016 2.365.000 87.69%
2017 2.137.000 -10.67%
2018 2.881.000 25.82%
2019 980.000 -193.98%
2020 630.000 -55.56%
2021 1.456.000 56.73%
2022 512.000 -184.38%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Apollo Endosurgery, Inc. Equity
Year Equity Growth
2005 5.350.267
2006 1.558.776 -243.24%
2007 6.335.228 75.4%
2008 3.569.800 -77.47%
2009 1.876.198 -90.27%
2010 3.007.302 37.61%
2011 629.024 -378.09%
2012 14.944.720 95.79%
2013 9.968.173 -49.92%
2014 15.816.426 36.98%
2015 10.531.991 -50.18%
2016 42.417.000 75.17%
2017 49.913.000 15.02%
2018 28.830.000 -73.13%
2019 2.123.000 -1257.98%
2020 6.751.000 68.55%
2021 61.237.000 88.98%
2022 32.594.000 -87.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Apollo Endosurgery, Inc. Assets
Year Assets Growth
2005 5.944.901
2006 2.354.235 -152.52%
2007 8.651.988 72.79%
2008 9.421.952 8.17%
2009 7.869.974 -19.72%
2010 23.839.022 66.99%
2011 17.943.210 -32.86%
2012 27.183.533 33.99%
2013 15.669.733 -73.48%
2014 20.958.170 25.23%
2015 11.612.445 -80.48%
2016 102.124.000 88.63%
2017 109.061.000 6.36%
2018 74.468.000 -46.45%
2019 74.582.000 0.15%
2020 77.437.000 3.69%
2021 131.528.000 41.13%
2022 110.231.000 -19.32%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Apollo Endosurgery, Inc. Liabilities
Year Liabilities Growth
2005 594.634
2006 795.459 25.25%
2007 2.316.760 65.67%
2008 5.852.152 60.41%
2009 5.993.776 2.36%
2010 20.831.720 71.23%
2011 17.314.186 -20.32%
2012 12.238.813 -41.47%
2013 5.701.560 -114.66%
2014 5.141.744 -10.89%
2015 1.080.454 -375.89%
2016 59.707.000 98.19%
2017 59.148.000 -0.95%
2018 45.638.000 -29.6%
2019 72.459.000 37.02%
2020 70.686.000 -2.51%
2021 70.291.000 -0.56%
2022 77.637.000 9.46%

Apollo Endosurgery, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.89
Net Income per Share
-0.98
Price to Earning Ratio
-10.2x
Price To Sales Ratio
7.54x
POCF Ratio
-13
PFCF Ratio
-17.05
Price to Book Ratio
12.47
EV to Sales
7.54
EV Over EBITDA
-20.69
EV to Operating CashFlow
-18.55
EV to FreeCashFlow
-17.05
Earnings Yield
-0.1
FreeCashFlow Yield
-0.06
Market Cap
0,58 Bil.
Enterprise Value
0,58 Bil.
Graham Number
4.2
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.98
Income Quality
0.78
ROE
-0.85
Return On Assets
-0.36
Return On Capital Employed
-0.39
Net Income per EBT
1.01
EBT Per Ebit
1.41
Ebit per Revenue
-0.36
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.27
Research & Developement to Revenue
0.15
Stock Based Compensation to Revenue
0.09
Gross Profit Margin
0.55
Operating Profit Margin
-0.36
Pretax Profit Margin
-0.51
Net Profit Margin
-0.52

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.77
Free CashFlow per Share
-0.84
Capex to Operating CashFlow
0.09
Capex to Revenue
-0.04
Capex to Depreciation
-0.93
Return on Invested Capital
-0.31
Return on Tangible Assets
-0.39
Days Sales Outstanding
71.19
Days Payables Outstanding
78.65
Days of Inventory on Hand
193.44
Receivables Turnover
5.13
Payables Turnover
4.64
Inventory Turnover
1.89
Capex per Share
-0.07

Balance Sheet

Cash per Share
1,40
Book Value per Share
0,80
Tangible Book Value per Share
0.59
Shareholders Equity per Share
0.8
Interest Debt per Share
1.52
Debt to Equity
1.75
Debt to Assets
0.52
Net Debt to EBITDA
-0
Current Ratio
2.35
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
1.75
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
15106000
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Apollo Endosurgery, Inc. Dividends
Year Dividends Growth

Apollo Endosurgery, Inc. Profile

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

CEO
Mr. Charles S. McKhann
Employee
202
Address
Building 1
Austin, 78746

Apollo Endosurgery, Inc. Executives & BODs

Apollo Endosurgery, Inc. Executives & BODs
# Name Age
1 Mr. John J. Molesphini
Executive Vice President of Operations
70
2 Dr. Sergey Kantsevoy M.D.
Co-Founder and Innovation Partner
70
3 Dr. Peter Benjamin Cotton M.D.
Co-Founder and Innovation Partner
70
4 Dr. Pankaj Jay Pasricha FACP, M.D., MBBS
Co-Founder
70
5 Mr. Jeffrey G. Black
Chief Financial Officer, Sec. & Treasurer
70
6 Mr. Anthony Kalloo M.D.
Co-Founder and Innovation Partner
70
7 Mr. Sydney Chung M.D.
Co-Founder and Innovation Partner
70
8 Dr. Robert Hawes M.D.
Co-Founder and Innovation Partner
70
9 Dr. Christopher J. Gostout M.D.
Co-Founder & Chief Medical Officer
70
10 Mr. Charles S. McKhann
Chief Executive Officer, Pres & Director
70

Apollo Endosurgery, Inc. Competitors